How a German Biotech's New Approach Could Change Heart Disease Treatment

Jan de Vries · 2026-08-28

There's a new player in the European biotech scene, and it's taking aim at one of medicine's toughest challenges. Revier Therapeutics, a startup based in Heidelberg, Germany, has just launched with a $6.4 million seed round to develop a new class of cardiometabolic therapies. That's right, they're tackling heart failure and cardiovascular disease with a fresh perspective. This isn't just another funding announcement. It's about a potential shift in how we treat millions of patients who currently have limited options. The round was led by the KHAN Technology Transfer Fund II, with High-Tech Gründerfonds (HTGF), VORNvc, and private investors through Revier Invest Heidelberg joining in. ### The Unmet Need in Heart Disease Let's talk about the problem for a second. Despite all the advances in cardiovascular medicine, millions of people are still stuck. We're talking about patients with HFpEF (heart failure with preserved ejection fraction) and ASCVD (atherosclerotic cardiovascular disease). They're facing a real shortage of targeted treatments that get to the root of their conditions. Prof. Eva van Rooij, the company's CEO and co-founder, puts it plainly: “We believe the next generation of cardiometabolic medicines needs to address the underlying disease-driving biology. That's the only way to deliver solutions that actually last for patients.” Their mission? To translate some pretty complex science into real therapies that can make a difference where it counts. ### A Different Kind of HDAC Strategy Here's where things get interesting. Revier is going after class IIa histone deacetylases (HDACs) – enzymes that play a key role in severe diseases. But they're doing it differently than anyone has before. - **First-in-class approach:** They've developed the first therapeutic strategy to *selectively* target these specific HDACs for cardiometabolic diseases. - **Oral small molecules:** Their treatments are designed to be taken orally, which is a big deal for patient convenience. - **Precision targeting:** The molecules aim to inhibit only the disease-causing activity while leaving healthy functions alone. Prof. Johannes Backs, the scientific founder, explains why this precision matters: “Earlier HDAC inhibitors targeted multiple classes broadly, which led to serious side effects. Our compounds are like smart missiles instead of carpet bombs.” ### What The Investors See The backers aren't just throwing money at another biotech. They see something specific here. Michael Hamacher from KHAN Technology Transfer Fund II points to Revier's “differentiated class IIa HDAC strategy” as having real potential to “unlock the therapeutic promise of HDAC biology” while avoiding the pitfalls of older approaches. He adds that combined with what he calls an “exceptional leadership team and deep scientific expertise,” the company has a shot at reshaping how we care for these patients. That's not small talk – that's investor conviction. ### Where The Money Goes So what's the plan for that $6.4 million? It's all about building momentum: - Advancing their preclinical pipeline, starting with HFpEF and ASCVD - Building out their operational, scientific, and clinical teams - Pushing their lead programs closer to actual clinical trials It's worth pausing here to think about the bigger picture. Europe's biotech ecosystem is maturing, and deals like this show how deep scientific expertise can attract serious investment. The coalition of regional stakeholders and investors, led by business developer Daniel Stern, suggests this isn't just about one company – it's about building a hub of innovation. The journey from lab discovery to patient treatment is long and expensive. But with this seed funding and their novel approach, Revier Therapeutics is betting they can navigate that path. For patients waiting for better options, that bet could mean everything. Only time will tell if their precision approach to HDAC inhibition becomes the next standard in cardiometabolic care, but they've certainly secured their chance to try.